En­her­tu nabs pri­or­i­ty re­view for NSCLC as As­traZeneca and Dai­ichi Sankyo con­tin­ue chart­ing a block­buster course

As As­traZeneca and Dai­ichi Sankyo con­tin­ue to out­line their block­buster plans for the an­ti­body-drug con­ju­gate En­her­tu, the FDA is giv­ing them an as­sist.

Reg­u­la­tors award­ed pri­or­i­ty re­view for the drug in pa­tients with HER2-pos­i­tive non-small cell lung can­cer who have re­ceived a pri­or sys­temic ther­a­py, the com­pa­nies an­nounced Tues­day. The de­ci­sion slots En­her­tu in for a pos­si­ble quick OK once the PDU­FA date comes along, slat­ed for some­time in the third quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER